Commercial interest waxes for IGF-1 blockers

Years of dashed expectations over insulin-like growth factor-1 (IGF-1) blockers have seemingly ended, as a rash of candidates jostles its way into clinical trials. Observers hold wary optimism for the prospects of IGF-1 blockers--long touted and even longer ignored.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2008-07, Vol.26 (7), p.719-720
Main Author: Osborne, Randy
Format: Article
Language:English
Subjects:
Agriculture
Antineoplastic Agents - administration & dosage
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedical Research - trends
Biomedicine
Biotechnology
Biotechnology industry
Clinical trials
Commerce - trends
Drug Design
Drug Industry - trends
Drug therapy
Health aspects
Humans
Insulin-like growth factor 1
Insulin-Like Growth Factor I - antagonists & inhibitors
Life Sciences
Lung cancer, Non-small cell
Monoclonal antibodies
Neoplasms - drug therapy
news
Pharmaceutical industry
Pharmacology
Product development
R&D
Research & development
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Years of dashed expectations over insulin-like growth factor-1 (IGF-1) blockers have seemingly ended, as a rash of candidates jostles its way into clinical trials. Observers hold wary optimism for the prospects of IGF-1 blockers--long touted and even longer ignored.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0708-719